1. Study: Biosimilars ‘fulfilling their promise’ of lowering biologic prices— After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaints --Zuckerberg cash helping to propel Chicago's biotech ambitions -- See more on our front page news
    Dismiss Notice

Why Amgen Is Up More Than 6% Today

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 11, 2022 at 4:22 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    • Amgen is well positioned to capitalize on an underserved weight-loss market.
    • While the company may soon face stiff competition on other fronts, the stock is holding up this year for good reason.

    article source